Key Points
- Insider sale: EVP Mark Goldsmith sold 120,000 shares on April 15 at an average price of $150.09 for proceeds of $18.01M, cutting his stake by 30.25% to 276,698 shares (worth ≈$41.53M).
- Large capital raise completed: Revolution closed concurrent upsized offerings — 12,147,887 common shares at $142 and $500M of 0.50% convertible senior notes due 2033 — raising roughly $2.225B gross, a move that bolsters the cash runway but is dilutive and may pressure near‑term share performance.
- Operational and market context: the company reported a Q that missed EPS estimates (‑$1.86 vs. ‑$1.56), has a market cap of ~$29.45B and a 52‑week range of $34.00–$155.70, while Wall Street consensus is broadly positive (majority Buy/Strong Buy) despite mixed analyst revisions and a consensus FY EPS forecast of about ‑3.49.
Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark Goldsmith sold 120,000 shares of the company's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total transaction of $18,010,800.00. Following the completion of the sale, the insider directly owned 276,698 shares of the company's stock, valued at $41,529,602.82. The trade was a 30.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Revolution Medicines Stock Performance
RVMD stock opened at $148.63 on Friday. The company has a market capitalization of $29.45 billion, a P/E ratio of -25.15 and a beta of 1.01. The company has a 50-day simple moving average of $103.12 and a 200 day simple moving average of $85.92. Revolution Medicines, Inc. has a fifty-two week low of $34.00 and a fifty-two week high of $155.70. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period last year, the business earned ($1.12) EPS. Sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Revolution Medicines
A number of institutional investors and hedge funds have recently bought and sold shares of RVMD. Nextech Invest Ltd. lifted its holdings in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. Millennium Management LLC lifted its holdings in Revolution Medicines by 681.8% in the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company's stock valued at $5,529,000 after acquiring an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Revolution Medicines by 14.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company's stock valued at $10,615,000 after acquiring an additional 37,345 shares during the last quarter. Invesco Ltd. lifted its holdings in Revolution Medicines by 19.3% in the 2nd quarter. Invesco Ltd. now owns 227,019 shares of the company's stock valued at $8,352,000 after acquiring an additional 36,760 shares during the last quarter. Finally, Jump Financial LLC lifted its holdings in Revolution Medicines by 87.9% in the 2nd quarter. Jump Financial LLC now owns 15,258 shares of the company's stock valued at $561,000 after acquiring an additional 7,137 shares during the last quarter. 94.34% of the stock is owned by institutional investors and hedge funds.
More Revolution Medicines News
Here are the key news stories impacting Revolution Medicines this week:
- Positive Sentiment: Takeover speculation persists after positive interpretation of daraxonrasib clinical data, which can support M&A interest and investor upside. Why Revolution Medicines still looks like a prime takeover target
- Positive Sentiment: Lifesci Capital nudged its Q4 2026 EPS forecast slightly higher (from -$2.09 to -$2.08), a small positive signal on model outlook and analyst sentiment.
- Neutral Sentiment: Public reporting noted the company entered underwriting agreements and moved to raise capital via equity and convertible notes — confirms the financing plan but adds no new terms beyond the filing coverage. Revolution Medicines Raises Capital via Equity and Convertible Notes
- Negative Sentiment: Revolution closed concurrent upsized offerings: 12,147,887 common shares at $142.00 and $500M of 0.50% convertible senior notes due 2033, raising ~$2.225B gross. The large equity issuance (including full underwriter option) is dilutive and often pressures near-term share price despite improving cash runway. Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings
- Negative Sentiment: HC Wainwright cut multiple quarterly and full‑year EPS forecasts materially (Q1–Q4 and FY2026 revisions lower), signaling weaker near‑term profitability expectations and adding downward pressure on sentiment.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on RVMD. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Evercore reaffirmed an "outperform" rating on shares of Revolution Medicines in a report on Tuesday. Benchmark reaffirmed an "overweight" rating on shares of Revolution Medicines in a report on Tuesday, February 17th. UBS Group assumed coverage on shares of Revolution Medicines in a report on Friday, February 27th. They issued a "buy" rating for the company. Finally, Jefferies Financial Group assumed coverage on shares of Revolution Medicines in a report on Monday, March 16th. They issued a "buy" rating for the company. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $78.94.
View Our Latest Report on Revolution Medicines
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.
The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
